Chandrudu S, Simerska P and Toth I. Chemical
methods for peptide and protein Production. Molecules
(2013) 18: 4373-88.
(2) Vlieghe P, Lisowski V, Martinez J and Khrestchatisky
M. Synthetic therapeutic peptides: science and market.
Drug Discov. Today (2010) 15: 40–56.
(3) Li H, Aneja R and Chaiken I. Click chemistry in
peptide-based drug design. Molecules (2013) 18: 9797-
817.
(4) Merrifield RB. Solid phase peptide synthesis. I. The
synthesis of a tetrapeptide. J. Am. Chem. Soc. (1963)
85: 2149–54.
(5) Dawson PE, Muir TW, Clark-Lewis I and Kent SB.
Synthesis of proteins by native chemical ligation.
Science (1994) 266: 776–79.
(6) Rosca EV, Koskimaki JE, Rivera CG, Pandey NB,
Tamiz AP and Popel AS. Anti-angiogenic peptides for
cancer therapeutics. Curr. Pharm. Biotechnol. (2011)
12: 1101–16.
(7) Karagiannis ED and Popel AS. Novel anti-angiogenic
1306
peptides derived from ELR-containing CXC
chemokines. J. Cell. Biochem. (2008) 104: 1356–63.
(8) Kritzer JA, Stephens OM, Guarracino DA, Reznika SK
and Schepartza A. β-Peptides as inhibitors of
proteinprotein interactions. Bioorg. Med. Chem.
(2005) 13: 11–6.
(9) Mochly-Rosen D and Qvit N. Peptide inhibitors of
protein protein interactions: from rational design to the
clinic. Chim. Oggi. (2010) 28: 14–6.
(10) Eldar-Finkelman H and Eisenstein M. Peptide
inhibitors targeting protein kinases. Curr. Pharm. Des.
(2009) 15: 2463–70.
(11) Tonelli R, Purgato S, Camerin C, Fronza R, Bolongna
F, Alboresi S, Franzoni M, Corradini R, Sforza S,
Faccini A, Shohet JM, Marchelli R and Pession A.
Antigene peptide nucleic acid specifically inhibits
MYCN expression in human neuroblastoma cells
leading to cell growth inhibition and apoptosis. Mol.
Cancer Ther. (2005) 4: 779–86.
(12) Kakde D, Jain D, Shrivastava V, Kakde R and Patil
AT. Cancer therapeutics-opportunities, challenges and
advances in drug delivery. J. Appl. Pharm. Sci. (2011)
1: 1–10.
(13) Zheng LH, Wang YJ, Sheng J, Wang F, Zheng Y, Lin
XK and Sun M. Antitumor peptides from marine
organisms. Mar. Drugs (2011) 9: 1840–59.
(14) Kolb HC, Finn MG and Sharpless KB. Click
chemistry: diverse chemical function from a few good
reactions. Angew. Chem. Int. Ed. (2001) 40: 2004–21.
(15) Kolb HC and Sharpless KB. The growing impact of
click chemistry on drug discovery. Drug Discov.
Today (2003) 8: 1128–37.
(16) Tilliet M, Lundgren S, Moberg C and Levacher V.
Polymer-bound pyridine-bis (oxazoline). Preparation
through click chemistry and evaluation in asymmetric
catalysis. Adv. Synth. Catal. (2007) 349: 2079–84.
(17) Lee JW, Kim JH, Kim BK, Kim JH, Shin WS and Jin SH.
Convergent synthesis of PAMAM dendrimers using click
chemistry of azide-functionalized PAMAM dendrons.
Tetrahedron (2006) 62: 9193–200.
(18) Nandivada H, Jiang X and Lahann J. Click chemistry:
versatility and control in the hands of materials
scientists. Adv. Mater. (2007) 19: 2197–208.
(19) Rozkiewicz DI, Gierlich J, Burley GA, Gutsmiedl K,
Carell T, Ravoo BJ and Reinhoudt DN. Transfer
printing of DNA by “click” chemistry. Chem. Bio.
Chem. (2007) 8: 1997–2002.
(20) Sharpless K B and Manetsch R. In situ click chemistry:
a powerful means for lead discovery. Exp. Opin. Drug
Discov. (2006) 1: 525–38.
(21) Nwe K and Brechbiel MW. Growing applications of
“click chemistry” for bioconjugation in contemporary
biomedical research. Cancer Biother. Radiopharm.
(2009) 24: 289–302.
(22) Gil MV, Arevalo MG and Lopez O. Click chemistry:
What’s in a name? Triazol synthesis and beyond.
Synthesis (2007) 11: 1589–620.
(23) Gouault N, Gupif JF, Sauleau A and David M.
ɣ-Methyl-substituted- ɣ-butyrolactones: solid-phase
Triazole peptides as anticancer agents
synthesis employing a cyclisation-cleavage strategy.
Tetrahedron Lett. (2000) 41: 7293–97.
(24) Gnanaprakazam A, Senthi kumar U and Reddy G.
Process for the preparation of tazobactam in pure form.
United States patent 7417143 (2008).
(25) Sultana N and Arayne MS. In-vitro activity of
cefadroxil, cephalexin, cefatrizine and cefpirome in
presence of essential and trace elements. Pak. J.
Pharm. Sci. (2007) 20: 305–10.
(26) Brik A, Muldoon J, Lin YC, Elder JH, Goodsell DS,
Olson AJ, Fokin VV, Sharpless KB and Wong CH.
Rapid diversity-oriented synthesis in microtiter plates
for in situ screening of HIV protease inhibitors. Chem.
Bio. Chem. (2003) 4: 1246-8.
(27) Soltis MJ, Yeh HJ, Cole KA, Whittaker N, Wersto RP
and Kohn EC. Identification and characterization of
human metabolites of CAI [5-amino-1-1(4′-
chlorobenzoyl-3, 5-dichlorobenzyl)-1, 2, 3-triazole-4-
carboxamide). Drug Metab. Dispos. (1996) 24: 799-
806.
(28) Alvarez R, Velazquez S, San-Felix A, Aquaro S, De
Clercq E, Perno CFN, Karlsson A, Balzarini J and
Camarasa MJ. 1, 2, 3-Triazole-[2,5-Bis-O-(tert-
butyldimethylsilyl)-.beta.-D-ribofuranosyl]-3′-spiro-
5′′-(4′′-amino-1′′,2′′-oxathiole 2′′,2′′-dioxide) (TSAO)
analogs: synthesis and anti-HIV-1 activity. J. Med.
Chem. (1994) 37: 4185-94.
(29) Hein CD, Liu XM and Wang D. Click chemistry, a
powerful tool for pharmaceutical sciences. Pharm.
Res. (2008) 25: 2216–30.
(30) Ahmaditaba MA, Houshdar Tehrani MH, Zarghi A,
Shahosseini S and Daraei B. Design, synthesis and
biological evaluation of novel peptide-like analogues
as selective COX-2 inhibitors. Iran. J. Pharm. Res.
(2018) 17: 87-92.
(31) Li Z, Yang J, Wang X, Li H, Liu C, Wang N, Huang
W and Qian H. Discovery of novel free fatty acid
receptor 1 agonists bearing triazole core via click
chemistry. Bioorg. Med. Chem. (2016) 24: 5449–54.
(32) Luna Vital DA, González de Mejía E, Dia VP and
Loarca-Piña G. Peptides in common bean fractions
inhibit human colorectal cancer cells. Food Chem.
(2014) 157: 347–55.
(33) Rabzia A, Khazaei M, Rashidi Z and Khazaei MR.
Synergistic anticancer effect of paclitaxel and
noscapine on human prostate cancer cell lines. Iran. J.
Pharm. Res. (2017) 16: 1432-42.
(34) Mohammadpour F, Ostad SN, Aliebrahimi S and
Daman Z. Anti-invasion effects of cannabinoids
agonist and antagonist on human breast cancer stem
cells. Iran. J. Pharm. Res. (2017) 16: 1479-86.
(35) Mosmann T. Rapid colorimetric assay for cellular
growth and survival: application to proliferation and
cytotoxicity assays. J. Immunol. Methods (1983) 65:
55-63.
(36) Dheer D, Singh V and Shankar R. Medicinal attributes
of 1, 2, 3-triazoles: current developments. Bioorg.
Chem. (2017) 71: 30–54.
(37) Haider S, Sarwar Alam M and Hamid H. 1, 2,
1307
Baharloui M et al. / IJPR (2019), 18 (3): 1299-1308
3-Triazoles: scaffold with medicinal significance.
Inflamm. Cell Signal. (2014) 1: e95.
(38) Huisgen R. 1, 3-dipolar cyloaddition chemistry. In:
Padwa A (ed.) 1st ed. John Wiley and Sons, New York
(1984) 1-176.
(39) Bock VD, Hiemstra H and van Maarseveen JH. CuI -
Catalyzed alkyne–azide “Click” cycloadditions from a
mechanistic and synthetic perspective. Eur. J. Org.
Chem. (2006) 12: 51-68
)